Abstract
Responses to venlafaxine treatment in major depressive disorder were stratified by COMT genotypes (Val158Met, rs4680) in a randomized, double-blind, placebo-controlled clinical trial. Improvements in depression scores among subjects with Val/Val genotypes were larger than those in Met/Met genotypes, suggesting that venlafaxine may alter noradrenergic flux differentially according to COMT activity.
Keywords:
COMT; Major depressive disorder; Venlafaxine.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Analysis of Variance
-
Antidepressive Agents, Second-Generation / therapeutic use*
-
Catechol O-Methyltransferase / genetics*
-
Cyclohexanols / therapeutic use*
-
Depressive Disorder, Major / drug therapy*
-
Depressive Disorder, Major / genetics*
-
Double-Blind Method
-
Female
-
Follow-Up Studies
-
Genotype
-
Humans
-
Male
-
Methionine / genetics
-
Middle Aged
-
Pharmacogenetics*
-
Polymorphism, Genetic / genetics
-
Psychiatric Status Rating Scales
-
Time Factors
-
Valine / genetics
-
Venlafaxine Hydrochloride
-
Young Adult
Substances
-
Antidepressive Agents, Second-Generation
-
Cyclohexanols
-
Venlafaxine Hydrochloride
-
Methionine
-
Catechol O-Methyltransferase
-
Valine